Amniotic Mesenchymal Stem Cells Can Enhance Angiogenic Capacity Via MMPs In Vitro and In Vivo

Overview

Journal Biomed Res Int

Publisher Wiley

Specialties Biomedical Engineering
Biotechnology
General Medicine

Date 2015 Oct 23

PMID 26491665

Citations 16

Authors

Fei Jiang

Jie Ma

Yi Liang

Yuming Niu

Ning Chen

Ming Shen

Affiliations

Soon will be listed here.

Abstract

The aim of this study was to evaluate the angiogenic capacity and proteolytic mechanism of coculture using human amniotic mesenchymal stem cells (hAMSCs) with human umbilical vein endothelial cells (HUVECs) in vivo and in vitro by comparing to those of coculture using bone marrow mesenchymal stem cells with HUVEC. For the in vivo experiment, cells (HUVEC-monoculture, HUVEC-hAMSC coculture, and HUVEC-BMMSC coculture) were seeded in fibrin gels and injected subcutaneously in nude mice. The samples were collected on days 7 and 14 and histologically analyzed by H&E and CD31 staining. CD31-positive staining percentage and vessel-like structure (VLS) density were evaluated as quantitative parameters for angiogenesis. The increases of CD31-positive staining area and VLS density in both HUVEC-hAMSC group and HUVEC-BMMSC group were found between two time points, while obvious decline of those was observed in HUVEC-only group. For the in vitro experiment, we utilized the same 3D culture model to investigate the proteolytic mechanism related to capillary formation. Intensive vascular networks formed by HUVECs were associated with hAMSCs or BMMSCs and related to MMP2 and MMP9. In conclusion, hAMSCs shared similar capacity and proteolytic mechanism with BMMSCs on neovascularization.

Citing Articles

Fetal adnexa-derived allogeneic mesenchymal stem cells for cardiac regeneration: the future trend of cell-based therapy for age-related adverse conditions.

Gorjipour F, Bohloolighashghaei S, Sotoudeheian M, Pazoki Toroudi H Hum Cell. 2025; 38(2):61.

PMID: 39998714 DOI: 10.1007/s13577-025-01190-2.

Potential Mechanism and Perspectives of Mesenchymal Stem Cell Therapy for Ischemic Stroke: A Review.

Zhu P, Tan H, Gao H, Wang J, Liu Y, Yang D Glob Med Genet. 2024; 11(4):278-284.

PMID: 39224463 PMC: 11368559. DOI: 10.1055/s-0044-1790231.

Treatment of cytokine release syndrome-induced vascular endothelial injury using mesenchymal stem cells.

Wang Y, Dong H, Dong T, Zhao L, Fan W, Zhang Y Mol Cell Biochem. 2023; 479(5):1149-1164.

PMID: 37392343 DOI: 10.1007/s11010-023-04785-1.

Biological properties and surgical applications of the human amniotic membrane.

Munoz-Torres J, Martinez-Gonzalez S, Lozano-Lujan A, Martinez-Vazquez M, Velasco-Elizondo P, Garza-Veloz I Front Bioeng Biotechnol. 2023; 10:1067480.

PMID: 36698632 PMC: 9868191. DOI: 10.3389/fbioe.2022.1067480.

The angiogenic properties of human amniotic membrane stem cells are enhanced in gestational diabetes and associate with fetal adiposity.

Klid S, Algaba-Chueca F, Maymo-Masip E, Guarque A, Ballesteros M, Diaz-Perdigones C Stem Cell Res Ther. 2021; 12(1):608.

PMID: 34930438 PMC: 8691045. DOI: 10.1186/s13287-021-02678-y.

References

Chen X, Aledia A, Popson S, Him L, Hughes C, George S . Rapid anastomosis of endothelial progenitor cell-derived vessels with host vasculature is promoted by a high density of cotransplanted fibroblasts. Tissue Eng Part A. 2009; 16(2):585-94. PMC: 2813071. DOI: 10.1089/ten.TEA.2009.0491. View

Rossi D, Pianta S, Magatti M, Sedlmayr P, Parolini O . Characterization of the conditioned medium from amniotic membrane cells: prostaglandins as key effectors of its immunomodulatory activity. PLoS One. 2012; 7(10):e46956. PMC: 3468614. DOI: 10.1371/journal.pone.0046956. View

Kim S, Zhang H, Kim C, An H, Kim J, Kim M . Amniotic mesenchymal stem cells have robust angiogenic properties and are effective in treating hindlimb ischaemia. Cardiovasc Res. 2011; 93(3):525-34. DOI: 10.1093/cvr/cvr328. View

Zvaifler N, Marinova-Mutafchieva L, Adams G, Edwards C, Moss J, Burger J . Mesenchymal precursor cells in the blood of normal individuals. Arthritis Res. 2000; 2(6):477-88. PMC: 17820. DOI: 10.1186/ar130. View

Rehman J, Traktuev D, Li J, Merfeld-Clauss S, Temm-Grove C, Bovenkerk J . Secretion of angiogenic and antiapoptotic factors by human adipose stromal cells. Circulation. 2004; 109(10):1292-8. DOI: 10.1161/01.CIR.0000121425.42966.F1. View

Li Y, Guo L, Ahn H, Kim M, Kim S . Amniotic mesenchymal stem cells display neurovascular tropism and aid in the recovery of injured peripheral nerves. J Cell Mol Med. 2014; 18(6):1028-34. PMC: 4508143. DOI: 10.1111/jcmm.12249. View

Verseijden F, Posthumus-van Sluijs S, Pavljasevic P, Hofer S, van Osch G, Farrell E . Adult human bone marrow- and adipose tissue-derived stromal cells support the formation of prevascular-like structures from endothelial cells in vitro. Tissue Eng Part A. 2009; 16(1):101-14. DOI: 10.1089/ten.TEA.2009.0106. View

Roubelakis M, Trohatou O, Anagnou N . Amniotic fluid and amniotic membrane stem cells: marker discovery. Stem Cells Int. 2012; 2012:107836. PMC: 3372280. DOI: 10.1155/2012/107836. View

ZuK P, Zhu M, Ashjian P, De Ugarte D, Huang J, Mizuno H . Human adipose tissue is a source of multipotent stem cells. Mol Biol Cell. 2002; 13(12):4279-95. PMC: 138633. DOI: 10.1091/mbc.e02-02-0105. View

10.

Petite H, Viateau V, Bensaid W, Meunier A, de Pollak C, Bourguignon M . Tissue-engineered bone regeneration. Nat Biotechnol. 2000; 18(9):959-63. DOI: 10.1038/79449. View

11.

Le Blanc K, Tammik C, Rosendahl K, Zetterberg E, Ringden O . HLA expression and immunologic properties of differentiated and undifferentiated mesenchymal stem cells. Exp Hematol. 2003; 31(10):890-6. DOI: 10.1016/s0301-472x(03)00110-3. View

12.

Konig J, Huppertz B, Desoye G, Parolini O, Frohlich J, Weiss G . Amnion-derived mesenchymal stromal cells show angiogenic properties but resist differentiation into mature endothelial cells. Stem Cells Dev. 2011; 21(8):1309-20. DOI: 10.1089/scd.2011.0223. View

13.

Ilancheran S, Moodley Y, Manuelpillai U . Human fetal membranes: a source of stem cells for tissue regeneration and repair?. Placenta. 2008; 30(1):2-10. DOI: 10.1016/j.placenta.2008.09.009. View

14.

Ferrara N, Alitalo K . Clinical applications of angiogenic growth factors and their inhibitors. Nat Med. 1999; 5(12):1359-64. DOI: 10.1038/70928. View

15.

Nauta A, Westerhuis G, Kruisselbrink A, Lurvink E, Willemze R, Fibbe W . Donor-derived mesenchymal stem cells are immunogenic in an allogeneic host and stimulate donor graft rejection in a nonmyeloablative setting. Blood. 2006; 108(6):2114-20. PMC: 1895546. DOI: 10.1182/blood-2005-11-011650. View

16.

Gruber R, Kandler B, Holzmann P, Vogele-Kadletz M, Losert U, Fischer M . Bone marrow stromal cells can provide a local environment that favors migration and formation of tubular structures of endothelial cells. Tissue Eng. 2005; 11(5-6):896-903. DOI: 10.1089/ten.2005.11.896. View

17.

Kinnaird T, Stabile E, Burnett M, Lee C, Barr S, Fuchs S . Marrow-derived stromal cells express genes encoding a broad spectrum of arteriogenic cytokines and promote in vitro and in vivo arteriogenesis through paracrine mechanisms. Circ Res. 2004; 94(5):678-85. DOI: 10.1161/01.RES.0000118601.37875.AC. View

18.

Jin M, Xie Y, Li Q, Chen X . Stem cell-based cell therapy for glomerulonephritis. Biomed Res Int. 2014; 2014:124730. PMC: 4070530. DOI: 10.1155/2014/124730. View

19.

Lovett M, Lee K, Edwards A, Kaplan D . Vascularization strategies for tissue engineering. Tissue Eng Part B Rev. 2009; 15(3):353-70. PMC: 2817665. DOI: 10.1089/ten.TEB.2009.0085. View

20.

Sun Q, Chen R, Shen Y, Mooney D, Rajagopalan S, Grossman P . Sustained vascular endothelial growth factor delivery enhances angiogenesis and perfusion in ischemic hind limb. Pharm Res. 2005; 22(7):1110-6. DOI: 10.1007/s11095-005-5644-2. View